%0 Journal Article
%T Targeting Trop-2 in solid tumors: future prospects
%A Aaron C Denson
%A Hassan Jadid
%A Jhanelle E Gray
%A Saif Zaman
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S162447
%X Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain overexpressed on a wide variety of tumors as well as its upregulated expression relative to normal cells. As a result, several Trop-2-targeted therapeutics have recently been developed for clinical use, such as anti-Trop-2 antibodies and Trop-2-targeted antibody¨Cdrug conjugates (ADC). Subsequently, multiple early-phase clinical trials have demonstrated safety and clinical benefit of Trop-2-based ADCs across multiple tumor types. This includes clinical benefit and tolerability in tumor types with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and small-cell lung cancer. In this review, we elaborate on all clinical trials involving Trop-2
%K Trop-2
%K trophoblast antigen 2
%K targeted therapy
%K antibody¨Cdrug conjugates
%K oncotargets
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402435/